Immunovant Chief Medical Officer Michael Geffner Departs Amid R&D Restructuring
Immunovant Inc. announced the departure of Chief Medical Officer Michael Geffner, effective November 21, 2025, as part of an R&D leadership restructuring under CEO Eric Venker. Dr. Geffner will continue consulting for the company until April 30, 2026.
Immunovant Inc. has announced that Michael Geffner, M.D., M.B.A., will no longer serve as Chief Medical Officer effective November 21, 2025, as part of a restructuring of the company’s R&D leadership under CEO Eric Venker, M.D., PharmD. Dr. Geffner will continue to provide consulting services to the company through April 30, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001764013-25-000153), on November 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
